Fixed-duration venetoclax in relapsed CLL, differing effects of invariant NK T cells, and under recognition of rare TERT variants in MDS

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Can You Ace the CLINQ ZERO Pop Quiz? Find Out Now! 6 min · 19 Sep 2026 · The Best 5 Minute Wine Podcast

Second Date Update Classics: Coffee Club + Falling to Pieces 36 min · 19 Sep 2026 · Brooke and Jeffrey

Trump bans CNN from the White House 18 min · 19 Sep 2026 · The Pat Kenny Show

What causes morning sickness during pregnancy? 9 min · 19 Sep 2026 · The Pat Kenny Show

The latest in Yemen 14 min · 19 Sep 2026 · The Pat Kenny Show

When You Love Someone...#DailyWisdom 0 min · 19 Sep 2026 · The Sadhguru Podcast - Of Mystics and Mistakes

Report any issue

Source

Recorded09 Sep 2021

Publisherfeeds.transistor.fm ↗

Handlerec:11742123

Show notes

In this week’s episode, we’ll review updated results of a phase 1b study that provide strong support for the use of fixed-duration venetoclax in patients with relapsed or refractory CLL. Next, we’ll review a research paper that provides new insights on the different subtypes of invariant natural killer T cells, which appear to have diverse immunoregulatory properties and anti-tumor effects. We will finish up with a report indicating that rare variants in the telomerase gene, TERT, are underrecognized in patients with myelodysplastic syndromes, providing a new insight into the germline genetic component of disease pathophysiology.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in